| PAREXEL International Corporation - SWOT Analysis | | | | million during FY2009, a decrease of 12.7% over |
| company profile is the essential source for top-level | | | | FY2008. The net profit was $39.3 million in FY2009, a |
| company data and information. PAREXEL International | | | | decrease of 39.2% over FY2008. |
| Corporation - SWOT Analysis examines the | | | | Scope of the Report |
| company's key business structure and operations, | | | | - Provides all the crucial information on PAREXEL |
| history and products, and provides summary analysis | | | | International Corporation required for business and |
| of its key revenue lines and strategy. | | | | competitor intelligence needs |
| PAREXEL International (PAREXEL) is a | | | | - Contains a study of the major internal and external |
| biopharmaceutical services company that provides | | | | factors affecting PAREXEL International Corporation |
| expertise in clinical research, medical communications | | | | in the form of a SWOT analysis as well as a |
| services, consulting, and informatics, and advanced | | | | breakdown and examination of leading product |
| technology products and services to the | | | | revenue streams of PAREXEL International |
| pharmaceutical, biotechnology, and medical device | | | | Corporation |
| industries. The company operates globally in the | | | | -Data is supplemented with details on PAREXEL |
| Americas, Europe, Asia Pacific, Middle East and Africa. | | | | International Corporation history, key executives, |
| It is headquartered at Waltham, Massachusetts and | | | | business description, locations and subsidiaries as well |
| employed 9,275 people as of June 2009. The | | | | as a list of products and services and the latest |
| company recorded revenues of $1,246.9 million during | | | | available statement from PAREXEL International |
| the financial year (FY) ended June 2009, an increase | | | | Corporation |
| of 7.2% over FY2008. The increase in revenues was | | | | For more information please visit: |
| due to strong demand for clinical research services. | | | | PH.NO. |
| The operating profit of the company was $75.6 | | | | |